Skip to main content
CELADON PHARMACEUTICALS PLC logo

CELADON PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · CEL ISIN · GB00BDQYGP38 LEI · 213800YXCATORT475807 IL Manufacturing
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-05-20 Annual Report
Country GB United Kingdom
Listing IL CEL

About CELADON PHARMACEUTICALS PLC

https://celadonpharma.co.uk/

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The company operates a licensed, 100,000 sq ft facility with EU-GMP certification for the indoor, hydroponic cultivation of high-THC cannabis and the extraction of cannabinoid Active Pharmaceutical Ingredients (API). Its primary focus is the chronic pain market, and it is conducting an MHRA conditionally approved clinical trial to generate data supporting the use of its medicines for this condition. Additionally, Celadon has an in-house research and development program focused on intellectual property generation and is involved in developing a licensed cannabinoid treatment for Autism Spectrum Disorder through a biopharma partnership.

Recent filings

Filing Released Lang Actions
Group of companies' accounts made up to 2024-12-31
Annual Report Classification · 95% confidence The document is titled “Annual Report and Accounts for the year ended 31 December 2024” and contains a full table of contents listing the Group Strategic Report, Report of the Directors, Report of the Independent Auditor, consolidated financial statements, notes, and company financial statements. It is a complete annual financial report, not merely an announcement or certification, matching the definition of an Annual Report. Therefore, it should be classified as a 10-K. FY 2024
2026-05-20 English
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from Celadon Pharmaceuticals Plc regarding the 'Result of General Meeting'. It provides a detailed table of voting results for specific resolutions (Cancellation, Adoption of new articles, Re-registration). While it mentions the cancellation of AIM trading, the primary purpose and content of the document is the declaration of the voting results from the general meeting, which fits the definition of DVA (Declaration of Voting Results & Voting Rights Announcements).
2025-07-28 English
Proposed Cancellation
Regulatory Filings Classification · 98% confidence The document is an official announcement from Celadon Pharmaceuticals PLC, identified by the RNS Number (3096P) and the date format typical of regulatory news services. The core subject is the 'Proposed cancellation of admission of Ordinary Shares to trading on AIM', 'Re-registration as a Private Limited Company', and a 'Notice of General Meeting'. The text explicitly mentions that a 'circular ("Circular")' containing details and a 'notice convening the General Meeting' will be posted to shareholders today (2 July 2025). Since the document itself is the announcement providing notice and summarizing the contents of the forthcoming Circular and General Meeting, it fits the description of a document announcing a corporate action that requires shareholder approval, which is often distributed via a Proxy Solicitation/Information Statement (DEF 14A/PSI) or a general regulatory announcement (RNS). Given that it contains the Notice of General Meeting and details about seeking shareholder approval for major corporate changes (delisting, re-registration), it strongly aligns with the purpose of a Proxy Statement or related meeting materials. However, the primary action being announced is the General Meeting itself, which is convened via the 'Notice of General Meeting' included within the announcement, and the document is essentially a summary/extract of the full Circular. The most fitting category for a document that announces a General Meeting and solicits shareholder votes on key resolutions (like delisting) is Proxy Solicitation & Information Statement (PSI). It is not the full Annual Report (10-K), nor is it just an Earnings Release (ER). It is a formal notice related to a shareholder vote, making PSI the best fit over the general RNS fallback, although RNS is also applicable due to the RNS header.
2025-07-02 English
Funding Update
Capital/Financing Update Classification · 99% confidence The document is identified by the RNS Number (2360P) and the source attribution to RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content provides a 'Funding Update' confirming receipt of new funds and mentioning an intention to proceed with a delisting. While it mentions a future delisting announcement, the primary nature of this specific filing is a regulatory update disseminated via the RNS system regarding financing and corporate action intentions. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like CAP (Capital/Financing Update) or DLST (Delisting Announcement) as a formal notice, and it is distributed via the official regulatory news service, the most appropriate general classification is Regulatory Filings (RNS). The document length is short (3440 chars), suggesting it is an announcement rather than a full report.
2025-07-01 English
Result of AGM
AGM Information Classification · 99% confidence The document is titled 'Result of Annual General Meeting' and explicitly details the poll results for various resolutions voted on at the AGM, including director re-elections and auditor appointments. This directly corresponds to the definition of AGM Information. Although it mentions a potential delisting and management changes, the primary content and purpose of this specific filing is reporting the outcome of the shareholder meeting. Therefore, the appropriate code is AGM-R.
2025-07-01 English
Funding and Operational Update, Delay in Results
Report Publication Announcement Classification · 100% confidence The document is an official announcement disseminated via RNS (RNS Number: 8949O) from Celadon Pharmaceuticals PLC. The primary subject is a 'Funding and Operational Update' which explicitly states a 'Delay in published Annual Report & Accounts' for the year ended 31 December 2024. It details new debt facilities (£1.0 million), potential future investment (£20.0 million), operational progress, and the consequence of the delay: suspension of trading on AIM until the audited Annual Report and Accounts are published. Since this document is an announcement *about* the delay of the Annual Report and provides operational/funding updates, it is not the full Annual Report (10-K) or the Interim Report (IR). It is a general regulatory announcement concerning material company events, including the status of required filings. Given the context of an RNS distribution and the nature of the content (updates on funding, operations, and filing delays), the most appropriate classification is Regulatory Filings (RNS), as it serves as a broad regulatory disclosure that doesn't fit the more specific categories like ER, CAP, or DIV, although it touches upon CAP elements. It is not a Report Publication Announcement (RPA) because it is not merely announcing the publication of another document; it is the substance of the update itself.
2025-06-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.